Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Protein purification: aspects of processes for pharmaceutical products.

Berthold W, Walter J.

Biologicals. 1994 Jun;22(2):135-50. Review.

PMID:
7917230
2.

The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.

Farshid M, Taffs RE, Scott D, Asher DM, Brorson K.

Curr Opin Biotechnol. 2005 Oct;16(5):561-7. Review.

PMID:
16095899
4.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
5.

Appropriate mammalian expression systems for biopharmaceuticals.

Werner RG, Noé W, Kopp K, Schlüter M.

Arzneimittelforschung. 1998 Aug;48(8):870-80. Review.

PMID:
9748718
6.

Analysis for residual host cell proteins and DNA in process streams of a recombinant protein product expressed in Escherichia coli cells.

Rathore AS, Sobacke SE, Kocot TJ, Morgan DR, Dufield RL, Mozier NM.

J Pharm Biomed Anal. 2003 Aug 21;32(6):1199-211.

PMID:
12907264
7.

Peptide mapping for detecting variants in protein products.

Garnick RL.

Dev Biol Stand. 1992;76:117-30.

PMID:
1478332
9.

Purified protein products of rDNA technology expressed in animal cell culture.

Lubiniecki AS, Lupker JH.

Biologicals. 1994 Jun;22(2):161-9. Review.

PMID:
7522477
10.

Validation of removal of human retroviruses.

Marcus-Sekura CJ.

Dev Biol Stand. 1991;75:133-43.

PMID:
1794615
11.

Micro biochemical engineering to accelerate the design of industrial-scale downstream processes for biopharmaceutical proteins.

Titchener-Hooker NJ, Dunnill P, Hoare M.

Biotechnol Bioeng. 2008 Jun 15;100(3):473-87. doi: 10.1002/bit.21788.

PMID:
18438873
12.

Current issues in viral assays and viral clearance evaluation.

Lubiniecki AS.

Dev Biol Stand. 1996;88:9-11.

PMID:
9119167
14.

Industry perspective for biotech products.

Möritz A.

Dev Biol (Basel). 2004;118:37-44.

PMID:
15645671
15.

Animal virus contaminants of biotechnology products.

Onions D.

Dev Biol (Basel). 2004;118:155-63. No abstract available.

PMID:
15645686
16.

Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.

Shi L, Chen Q, Norling LA, Lau AS, Krejci S, Xu Y.

Biotechnol Bioeng. 2004 Sep 30;87(7):884-96.

PMID:
15334415
17.

Strategies to avoid virus transmissions by biopharmaceutic products.

Werz W, Hoffmann H, Haberer K, Walter JK.

Arch Virol Suppl. 1997;13:245-56.

PMID:
9413543
18.

Rational and systematic protein purification process development: the next generation.

Nfor BK, Verhaert PD, van der Wielen LA, Hubbuch J, Ottens M.

Trends Biotechnol. 2009 Dec;27(12):673-9. doi: 10.1016/j.tibtech.2009.09.002. Epub 2009 Oct 6.

PMID:
19815300
19.

Biotechnology: an introduction to recombinant DNA technology and product availability.

Evens RP, Witcher M.

Ther Drug Monit. 1993 Dec;15(6):514-20. Review.

PMID:
8122286
20.

Examination of the biological safety of a drug derived from mammalian organs.

Hübner GE, Koch RC, Sprenger KB, Stadler PJ, Gölker CF.

Arzneimittelforschung. 1996 Jun;46(6):657-61.

PMID:
8767361

Supplemental Content

Support Center